Avalo Therapeutics Inc. (AVTX)
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 178,100 shares of the company's stock, valued at approximately $2,264,000. Avalo Therapeutics comprises 1.4% of Ally Bridge Group
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for targeting interleukin-1 beta (IL-1β) in the disease. Company focus and
Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results
Avalo Therapeutics' value mostly hinges on AVTX-009. This is an IL-1β mAb in a Phase 2 LOTUS trial for hidradenitis suppurativa. This Phase 2 trial should give us topline results by mid-2026, which I consider its most significant near-term value driver at this point. AVTX-009 also seems to have higher affinity and half-life versus Lutikizumab, which could allow for fewer doses and stronger efficacy.
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases.
The 3 Best Personalized Nutrition Stocks to Buy Now
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
